Krystal Biotech, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases. The Company's lead product candidate includes KB103, which is in preclinical studies to treat dystrophic epidermolysis bullosa, a genetic disease. It also develops KB104 that is in preclinical studies to treat Netherton syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders.
Pittsburgh, US
Size (employees)
6 (est)
Krystal Biotech was founded in 2015 and is headquartered in Pittsburgh, US
Report incorrect company information

Krystal Biotech Office Locations

Krystal Biotech has an office in Pittsburgh
Pittsburgh, US (HQ)
701 2100 Wharton St
Show all (1)
Report incorrect company information

Krystal Biotech Financials and Metrics

Krystal Biotech Financials


Net income (FY, 2016)

(1.2 m)

EBIT (FY, 2016)

(1.1 m)

Cash (5-Mar-2018)

1.9 m
USDFY, 2016

General and administrative expense

402 k

R&D expense

741 k

Operating expense total

1.1 m


(1.1 m)
USDFY, 2016


1.9 m

Prepaid Expenses

246 k

Current Assets

2.2 m


13 k
USDFY, 2016

Net Income

(1.2 m)

Depreciation and Amortization

2 k

Cash From Operating Activities

(1.3 m)

Purchases of PP&E

(15 k)
USDY, 2016

Financial Leverage

7.6 x
Show all financial metrics
Report incorrect company information